Choosing the right antihypertensive drug to avoid intradialytic hypotension
Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii47-ii54
DOI: 10.1093/ckj/sfaf315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 13.10.2025. Verfasst von Carmine Zoccali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Renal Research Institute, New York, NY, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Intradialytic hypotension (IDH) is a significant complication in haemodialysis (HD) patients, affecting cardiovascular stability and treatment outcomes. Antihypertensive medications, while crucial for blood pressure control, can exacerbate IDH, necessitating careful drug selection and management. This review highlights the differential effects at the HD population level of drug classes such as beta and alpha-beta blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II antagonists, diuretics and calcium antagonists. Beta and alpha-beta blockers are linked to a higher risk of IDH due to their impact on heart rate and myocardial contractility, which can impair cardiovascular reflexes during dialysis. ACEIs and angiotensin II antagonists may increase the risk of hypotension by reducing vascular resistance. Diuretics can worsen volume depletion, especially when combined with ultrafiltration. Conversely, calcium antagonists have been associated with a lower risk of IDH in low-power clinical studies. Target trials represent an opportunity to generate high-quality evidence in the absence of randomized controlled trial (RCT) data. To fill the knowledge gap, this review discusses a target trial emulation study by Zoccali et al. that provides insights into the comparative risks of antihypertensive drugs using observational data. This study underscores the need for individualized treatment plans and highlights the importance of further research, particularly RCTs, to validate findings and explore long-term cardiovascular outcomes. This review aims to guide clinicians in optimizing antihypertensive therapy for HD patients, balancing effective blood pressure control with minimizing IDH risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Research Institute, New York, NY, USA.
- Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy.
- Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), c/o Nefrologia, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
- CNR-IFC, Institute of Clinical Physiology, Research Unit of Clinical Epidemiology, Reggio Calabria, Italy.
- Fresenius Medical Care, Global Medical Office, Waltham, MA, USA.
- Fresenius Medical Care, Global Medical Office, Palazzo Pignano, Italy.
ORCID-Profile: Carmine Zoccali
Zitieren
APA
Zoccali, C., Tripepi, G., Mallamaci, F., Usvyat, L. S., Maddux, F. W., & Stuard, S. (2025). Choosing the right antihypertensive drug to avoid intradialytic hypotension. Clinical Kidney Journal, 18(Supplement_2), ii47-ii54. https://doi.org/10.1093/ckj/sfaf315
Vancouver
Zoccali C, Tripepi G, Mallamaci F, Usvyat LS, Maddux FW, Stuard S. Choosing the right antihypertensive drug to avoid intradialytic hypotension. Clinical Kidney Journal. 2025;18(Supplement_2):ii47-ii54. doi:10.1093/ckj/sfaf315
BibTeX
@article{Zoccali2025,
author = {Zoccali, Carmine and Tripepi, Giovanni and Mallamaci, Francesca and Usvyat, Len S and Maddux, Franklin W and Stuard, Stefano},
title = {Choosing the right antihypertensive drug to avoid intradialytic hypotension},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {Supplement_2},
pages = {ii47--ii54},
doi = {10.1093/ckj/sfaf315}
}
EUVIMED